Week Ending February 28, 2022

Hepatitis C seroprevalence among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an integrated bio-behavioral survey
“Understanding the extent of viral hepatitis burden in specific subgroups, such as pregnant women and people living with HIV/AIDS (PLWHA), and their geographic distribution is essential for evidence-informed policy and mobilizing resources for targeted treatment and prevention efforts. However, in Cambodia, the epidemiology of hepatitis C remains uncertain. We estimated the hepatitis C virus (HCV) burden and transmission risk factors among PLWHA and pregnant women attending antenatal care (ANC) in Cambodia.”

Expert: Patients with cirrhosis have a ‘sufficiently high risk’ for liver cancer
“The incidence of liver cancer is increasing several-fold, particularly within the South and the West. … At the same time that the incidence is going up, so too is the mortality, nearly two-fold,” Elliot B. Tapper, MD, associate professor of medicine at the University of Michigan, said. “When you look underneath the hood to ask whom this is happening to, you can see some very important clues to tell us a little bit about where this disease is going.”

A Modelling Analysis of Global Shift in Hepatitis C Virus Prevalence and Care Cascades Between 2015 and 2020
“Many nations and territories have been making progress toward hepatitis C virus (HCV) elimination since the introduction of the first global hepatitis elimination targets in 2016 and until the COVID-19 pandemic began in early 2020. For a study, researchers assessed HCV burden in 2020 and set a goal to anticipate HCV burden by 2030 based on existing trends. A literature study, Delphi method, and mathematical modeling were used to estimate HCV prevalence (viraemic infection, defined as HCV RNA-positive cases). It was also essential to a cascade of care among people of all ages (age 0 years from birth) from January 1, 2015, to December 31, 2030.”

Pharmacist Medication Insights: Mavyret for Hepatitis C
“Glecaprevir and pibrentasvir (Mavyret) is a fixed-dose combination indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotypes 1-6 infections without cirrhosis or with compensated cirrhosis.”

Hepatitis C Virus Positivity Linked to Schizophrenia Development
“Jur-Shan Cheng, Ph.D., from Chang Gung University in Taoyuan, Taiwan, and colleagues conducted a nationwide study using the Taiwan National Health Insurance Research Database from 2003 to 2012 to examine the potential association between HCV infection and schizophrenia. Three propensity score-matched cohorts were included from a total population of 19,298,735 individuals: 8,931 HCV-infected patients receiving interferon-based therapy for at least six months (HCV-treated); 17,862 individuals with HCV not receiving treatment (HCV-untreated); and 17,862 HCV-uninfected individuals. Overall, 82.81 percent of the total sample were aged 40 years or older.”

Can COVID-19 Testing Technologies Apply to Hepatitis C and Other Diseases?
“What will be the next game-changing advancement in the treatment of hepatitis C? If Australia, France and the United Kingdom offer any indication, the arrival of automated molecular tests could boost hepatitis C treatment rates, according to the New York Times.”